These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 9151912)

  • 21. Postoperative adjuvant locoregional chemotherapy in patients with hepatocellular carcinoma.
    Izumi R; Shimizu K; Miyazaki I
    Hepatogastroenterology; 1996; 43(12):1415-20. PubMed ID: 8975941
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial.
    Lai EC; Lo CM; Fan ST; Liu CL; Wong J
    Arch Surg; 1998 Feb; 133(2):183-8. PubMed ID: 9484732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized controlled trial to compare the dose of adjuvant chemotherapy after curative resection of hepatocellular carcinoma.
    Kwok PC; Lam TW; Lam PW; Tang KW; Chan SC; Hwang JS; Cheung MT; Tang DL; Chung TK; Chia NH; Wong WK; Chan MK; Lo HY; Lam WM
    J Gastroenterol Hepatol; 2003 Apr; 18(4):450-5. PubMed ID: 12653895
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant arterial infusion chemotherapy after resection of hepatocellular carcinoma with portal thrombosis: a pilot study.
    Niguma T; Mimura T; Tutui N
    J Hepatobiliary Pancreat Surg; 2005; 12(3):249-53. PubMed ID: 15995815
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognosis of patients with hepatocellular carcinoma treated solely with transcatheter arterial chemoembolization: risk factors for one-year recurrence and two-year mortality (preliminary data).
    Matsuda M; Omata F; Fuwa S; Saida Y; Suzuki S; Uemura M; Ishii N; Iizuka Y; Fukuda K; Fujita Y
    Intern Med; 2013; 52(8):847-53. PubMed ID: 23583987
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma.
    Kim SJ; Seo HY; Choi JG; Sul HR; Sung HJ; Park KH; Choi IK; Oh SC; Yoon SY; Seo JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
    Cancer Chemother Pharmacol; 2006 Apr; 57(4):436-42. PubMed ID: 16049620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The value of portal vein chemotherapy after radical resection in delaying intrahepatic recurrence of stage II primary hepatocellular carcinoma].
    Zhang GQ; Ge L; Ding W; Li HJ
    Ai Zheng; 2008 Dec; 27(12):1297-301. PubMed ID: 19079997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospective adjuvant therapy with mitomycin C and carmofur (HCFU) for colorectal cancer, 10-year follow-up: Tokai HCFU Study Group, the first study for colorectal cancer.
    Ito K; Yamaguchi A; Miura K; Kato T; Koike A; Takagi H
    J Surg Oncol; 1996 May; 62(1):4-9. PubMed ID: 8618399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Post-operative adjuvant chemotherapy for colorectal cancer with 5-fluorouracil (5-FU) infusion combined with 1-hexylcarbamoyl-5-fluorouracil (HCFU) oral administration after curative resection.
    Iwagaki H; Tanaka N; Esato K; Kaibara N; Sano K; Dohi K; Toge T; Nakamura T; Nakasato H; Orita K
    Anticancer Res; 2001; 21(6A):4163-8. PubMed ID: 11911312
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized controlled trial of the efficacy of adjuvant immunochemotherapy and adjuvant chemotherapy for colorectal cancer, using different combinations of the intracutaneous streptococcal preparation OK-432 and the oral pyrimidines 1-hexylcarbamoyl-5-fluorouracil and uracil/tegafur.
    Watanabe M; Nishida O; Kunii Y; Kodaira S; Takahashi T; Tominaga T; Hojyo K; Kato T; Niimoto M; Kunitomo K; Isomoto H; Ohashi Y; Yasutomi M
    Int J Clin Oncol; 2004 Apr; 9(2):98-106. PubMed ID: 15108041
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant hepatic arterial infusion chemotherapy with 5-Fluorouracil and interferon after curative resection of hepatocellular carcinoma: a preliminary report.
    Kumamoto T; Tanaka K; Matsuo K; Takeda K; Nojiri K; Mori R; Taniguchi K; Matsuyama R; Ueda M; Akiyama H; Ichikawa Y; Ota M; Endo I
    Anticancer Res; 2013 Dec; 33(12):5585-90. PubMed ID: 24324102
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatocellular carcinoma: resection with adjuvant hepatic artery infusion therapy vs resection alone. A systematic review and meta-analysis.
    Moran A; Ramos LF; Picado O; Pendola F; Sleeman D; Dudeja V; Merchant N; Yakoub D
    J Surg Oncol; 2019 Mar; 119(4):455-463. PubMed ID: 30575028
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II intravenous study of epirubicin with 5-fluorouracil in patients with advanced hepatocellular carcinoma.
    Kajanti MJ; Pyrhönen SO
    Eur J Cancer; 1991; 27(12):1620-2. PubMed ID: 1664219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of transcatheter arterial infusion of anticancer agents with lipiodol to prevent recurrence of hepatocellular carcinoma after hepatic resection.
    Tanaka K; Shimada H; Togo S; Takahashi T; Endo I; Sekido H; Yoshida T
    Hepatogastroenterology; 1999; 46(26):1083-8. PubMed ID: 10370671
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized controlled trial of 5-fluorouracil (5-FU) infusion combined with 1-hexylcarbamoyl-5-fluorouracil (HCFU) oral administration and HCFU alone as postoperative adjuvant chemotherapy for colorectal cancer.
    Iwagaki H; Tanaka N; Esato K; Kaibara N; Sano K; Dohi K; Nakamura T; Nakasato H; Orita K
    Anticancer Res; 2000; 20(5C):3727-34. PubMed ID: 11268446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma.
    Zhu AX; Fuchs CS; Clark JW; Muzikansky A; Taylor K; Sheehan S; Tam K; Yung E; Kulke MH; Ryan DP
    Oncologist; 2005; 10(6):392-8. PubMed ID: 15967833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvant hepatic intra-arterial chemotherapy after potentially curative hepatectomy for liver metastases from colorectal cancer: a pilot study.
    Moriya Y; Sugihara K; Hojo K; Makuuchi M
    Eur J Surg Oncol; 1991 Oct; 17(5):519-25. PubMed ID: 1936300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anti-cancer drugs (epirubicin, cisplatin, mitomycin c, 5-fluorouracil) compared with TACE with epirubicin for treatment of hepatocellular carcinoma.
    Sahara S; Kawai N; Sato M; Tanaka T; Ikoma A; Nakata K; Sanda H; Minamiguchi H; Nakai M; Shirai S; Sonomura T
    Cardiovasc Intervent Radiol; 2012 Dec; 35(6):1363-71. PubMed ID: 22358993
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prophylactic chemolipiodolization for postoperative hepatoma patients.
    Shimoda M; Bando T; Nagata T; Shirosaki I; Sakamoto T; Tsukada K
    Hepatogastroenterology; 2001; 48(38):493-7. PubMed ID: 11379340
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II trial of transcatheter arterial infusion chemotherapy with an epirubicin-Lipiodol emulsion for advanced hepatocellular carcinoma refractory to transcatheter arterial embolization.
    Tanaka T; Ikeda M; Okusaka T; Ueno H; Morizane C; Ogura T; Hagihara A; Iwasa S
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):683-8. PubMed ID: 17541589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.